Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > RUSNANO Set to Invest in Drugs for Treating Cancer

The Supervisory Council of RUSNANO has approved a project to produce nanodrugs with targeted delivery for treatment of malignant neoplasms. Total budget for the project is 3.9 billion rubles of which RUSNANO will invest 1.299 billion rubles.

RUSNANO Set to Invest in Drugs for Treating Cancer

Russia | Posted on February 15th, 2010

When project goals have been fulfilled, Russia will have fully operating production facilities turning out effective, affordable cancer-fighting drugs with systems of targeted delivery—liposomes, immunoliposomes, and monoclonal antibodies.

Liposomal preparations are vesicles of about 100 nm composed of one or several layers of phospholipids containing an active drug stimulant and an aqueous phase. Liposomes relate to systems of passive targeted deliver—they are released from the bloodstream into tissue where permeability of the vessel is higher, that is, where the malignant tumor has occurred.

Immunoliposomes combine passive targeted delivery with an active system. Antibodies fixed to their surface areas are capable of recognizing tumor-specific molecular markers (tumor-associated antibodies). There is also a class of nanopreparations with active targeted delivery—monoclonal antibodies to tumor antigens that destroy malignant cells with powerful agents. These antibodies are generated in plant cells.

Production of liposome, based on doxorubicin, lizomustin, tsifelin, aranoz, and bacteriochlorin as well as immunoliposome and monoclonal antibodies is slated to begin in 2013-2014.

The N.N. Blokhin Cancer Research Centre of the Russian Academy of Medical Sciences—applicant and primary developer of the anti-cancer drugs with this new form of delivery—is the only medical institute in Russia that conducts the entire development cycle for domestic anti-tumor drugs: from the scientific idea to the introduction of new pharmaceuticals into medical practice.

Pharmaceutical company Medsintez of Novouralsk (Sverdlovsk Oblast) is the coinvestor. Its manufacturing facilities will be the main production site for commercialization and release of the anti-neoplasm nanodrugs that the Blokhin Cancer Research Centre develops.

"Production of highly effective anti-cancer drugs in Russia will lower death rates from cancer among all population groups; it will increase the average lifespan and improve the quality of life for those who are ill," noted RUSNANO Managing Director Olga Shpichko. "Lower prices will not only improve accessibility of the drugs but also allow the government to increase the amount of drugs it purchases for target programs without changing the budget."


The Russian Corporation of Nanotechnologies (RUSNANO) was established in 2007 by the Federal law ¹ 139-FZ to enable Government policy in the field of Nanotechnology.

To accomplish this task, RUSNANO co-invests in nanotechnology industry projects that have high commercial potential or social benefit. Early-stage investment by RUSNANO lowers the risk of its investment partners from the private sector.

RUSNANO participates in building nanotechnology infrastructure, which includes the nanotechnology centers of excellence, business incubators and early stage investment funds. RUSNANO provides scientific and educational programs that are required for its investment projects to succeed, and also supports the popularization of nanoscience and nanotechnology. RUSNANO selects promising spheres for investment based on longer-term sight created by the leading Russian and world experts.

To assist the Russian nanotechnology industry advance to the global market and strengthening of its international links RUSNANO develops partnerships with the leading nanotechnology centers in the world and organizes the annual Nanotechnology International Forum in Russia.

For more information, please click here

RUSNANO international press office:
Anna Fradkova, press-secretary of the international press office
P.: +7 495 5424444 add.1424
M.: +7 985 7299860

Copyright © RUSNANO

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Unusual quantum liquid on crystal surface could inspire future electronics October 22nd, 2016

Nanoparticle vaccinates mice against dengue fever October 21st, 2016

New perovskite solar cell design could outperform existing commercial technologies: Stanford, Oxford team creates high-efficiency tandem cells October 21st, 2016

Study explains strength gap between graphene, carbon fiber: Rice University researchers simulate defects in popular fiber, suggest ways to improve it October 19th, 2016


New nanomedicine approach aims to improve HIV drug therapies October 24th, 2016

Nanosciences: Genes on the rack October 21st, 2016

Nanoparticle vaccinates mice against dengue fever October 21st, 2016

Tiny gold particles could be the key to developing a treatment for pancreatic cancer October 19th, 2016


When quantum scale affects the way atoms emit and absorb particles of light: Exact simulation lifts the 80-year-old mystery of the degree to which atoms can be dressed with photons October 24th, 2016

Nanoantenna lighting-rod effect produces fast optical switches October 24th, 2016

New nanomedicine approach aims to improve HIV drug therapies October 24th, 2016

New method increases energy density in lithium batteries: Novel technique may lead to longer battery life in portable electronics and electrical vehicles October 24th, 2016


New nanomedicine approach aims to improve HIV drug therapies October 24th, 2016

Nanosciences: Genes on the rack October 21st, 2016

Nanoparticle vaccinates mice against dengue fever October 21st, 2016

Tiny gold particles could be the key to developing a treatment for pancreatic cancer October 19th, 2016

Alliances/Trade associations/Partnerships/Distributorships

Enterprise In Space Partners with Sketchfab and 3D Hubs for NewSpace Education October 13th, 2016

Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B October 6th, 2016

STMicroelectronics’ Semiconductor Chips Contribute to Connected Toothbrush from Oral-B That Sees What You Don’t: Microcontroller and Accelerometer help brushers clean their teeth more effectively October 4th, 2016

Leti to Tackle Tomorrow's Research Strategies with Stanford University’s SystemX Alliance: French R&D Center Is the First Research Institute to Join the Collaboration and Provides Bridges Between Academia and Industry, Leveraging Alliance’s Potential October 4th, 2016


DryWired's Liquid Nanotint to be the first nano-insulation in a Federal building: 250,000 federal buildings, most with uninsulated glass October 12th, 2016

Revolutionary Composite Gas Transition Seal October 4th, 2016

SENAI Outfits New Tribology Lab with Bruker UMT TriboLab Systems: Brazil’s National Service for Industrial Training Invests in Six Bruker Tribometers September 14th, 2016

FEI Celebrates Shipment of 1,000th Helios DualBeam System: FEI’s Helios Family has lead the DualBeam technology race and is widely used across the semiconductor, materials science, life sciences and oil & gas industries August 31st, 2016

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project